MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

RecruitingOBSERVATIONAL
Enrollment

222

Participants

Timeline

Start Date

October 15, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer
Interventions
OTHER

Genomic Prostate Score assay and Multi-parametric magnetic resonance imaging study of the prostate

The Genomic Prostate Score is a 17 gene relative expression assay used to predict the presence of adverse pathologic findings at radical prostatectomy. This test is used to determine appropriateness for active surveillance. Prostate MRI is a prostate imaging test that has been shown to improve the detection of clinically significant prostate cancer using a PI-RADS scoring system. It relies on T2-weighted imaging, diffusion weighted imaging, dynamic contrast enhancement, and apparent diffusion coefficient to differentiate prostate cancer from normal prostate parenchyma and prostatitis.

Trial Locations (2)

60611

ACTIVE_NOT_RECRUITING

Northwestern University, Chicago

60612

RECRUITING

University of Illinois at Chicago, Chicago

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Northwestern University

OTHER